Risk factors for recurrence of primary biliary cholangitis after liver transplantation in female patients: A Japanese multicenter retrospective study

Tomomi Kogiso, Hiroto Egawa, Satoshi Teramukai, Makiko Taniai, Etsuko Hashimoto, Katsutoshi Tokushige, Shotaro Sakisaka, Satomi Sakabayashi, Masakazu Yamamoto, Koji Umeshita, Shinji Uemoto – 16 May 2017 – Primary biliary cholangitis (PBC) is diagnosed mainly in female individuals, and risk factors for PBC recurrence (rPBC) after liver transplantation (LT) from cadaveric donors have been reported. We conducted a retrospective multicenter study of rPBC in female patients after living‐donor LT (LDLT).

Hepatic natural killer T‐cell and CD8+ T‐cell signatures in mice with nonalcoholic steatohepatitis

Jashdeep Bhattacharjee, Michelle Kirby, Samir Softic, Lili Miles, Rosa‐Maria Salazar‐Gonzalez, Pranav Shivakumar, Rohit Kohli – 16 May 2017 – Hepatic inflammation is a key pathologic feature of nonalcoholic steatohepatitis (NASH). Natural killer T (NKT) cells and clusters of differentiation (CD)8+ T‐cells are known to play an important role in obesity‐related adipose tissue inflammation. We hypothesized that these same inflammatory phenotypes would be present in progressive NASH.

The novel intracellular protein CREG inhibits hepatic steatosis, obesity, and insulin resistance

Quan‐Yu Zhang, Ling‐Ping Zhao, Xiao‐Xiang Tian, Cheng‐Hui Yan, Yang Li, Yan‐Xia Liu, Pi‐Xiao Wang, Xiao‐Jing Zhang, Ya‐Ling Han – 15 May 2017 – Cellular repressor of E1A‐stimulated genes (CREG), a novel cellular glycoprotein, has been identified as a suppressor of various cardiovascular diseases because of its capacity to reduce hyperplasia, maintain vascular homeostasis, and promote endothelial restoration. However, the effects and mechanism of CREG in metabolic disorder and hepatic steatosis remain unknown.

Safety and efficacy of current direct‐acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV‐TARGET study

Varun Saxena, Vandana Khungar, Elizabeth C. Verna, Josh Levitsky, Robert S. Brown, Mohamed A. Hassan, Mark S. Sulkowski, Jacqueline G. O'Leary, Farrukh Koraishy, Joseph S. Galati, Alexander A. Kuo, Monika Vainorius, Lucy Akushevich, David R. Nelson, Michael W. Fried, Norah Terrault, K. Rajender Reddy – 15 May 2017 – Data outside of clinical trials with direct‐acting antiviral regimens with or without ribavirin as treatment of chronic hepatitis C virus in solid organ transplant recipients are limited.

Subscribe to